Table 3.
Annual costs and health state utilities for chronic hepatitis B
| Parameter | Base-case estimate TL (€) | (range) | References |
|---|---|---|---|
| Drug costs (year 2010 values) | |||
| Lamivudine treatment (100 mg) | 1,176 (585) | 884–1,470 (439–731) | [45] |
| Adefovir salvage treatment (10 mg) | 12,012 (5,976) | 9,009–15,015 (4,482–7,470) | [45] |
| Entecavir treatment (0.5 mg) | 11,292 (5,618) | 8,469–14,115 (4,214–7,022) | [45] |
| Tenofovir (300 mg) | 8,028 (3,994) | 6,021–10,035 (2,996–4,992) | [45] |
| Peg-INF alfa 2a (INJVL 180MCG/ML) | 19,344 (9,624) | 14,508–24,180 (7,218–12,030) | [45] |
| Medical management costs | Personal communicationa | ||
| Monitoring of CHB | 720 (358) | 540–900 (269–627) | |
| Compensated Cirrhosis | 1,204 (602) | 903–1,505 (452–752) | |
| Decompensated Cirrhosis | 5,364 (2,668) | 4,023–6,705 (2,001–3,335) | |
| Hepatocellular carcinoma | 14,300 (7,114) | 10,725–17,875 (5,336–8,892) | |
| Liver transplantation | 174,050 (86,592) | 130,538–217,562 (64,944–108,240) | |
| Health state utilitiesb | |||
| Durable response to treatment | 1.00 | (0.95–1.00) | [46] |
| Chronic HBV | 0.68 | (0.66–0.70) | [46] |
| Compensated cirrhosis | 0.69 | (0.66–0.71) | [46] |
| Decompensated cirrhosis | 0.35 | (0.32–0.37) | [46] |
| Hepatocellulr carcinoma | 0.38 | (0.36–0.41) | [46] |
| Liver transplantation | 0.67 | (0.64–0.69) | [46] |
CHB chronic hepatitis B, HBV hepatitis B virus
aObtained from a retrospective analysis of medical records of a sample of 3,000 hospital admissions unpublished work
bSee Levy et al. (Ref. [46]) for the age-specific utilities